CH681305A5 - - Google Patents

Download PDF

Info

Publication number
CH681305A5
CH681305A5 CH1901/92A CH190192A CH681305A5 CH 681305 A5 CH681305 A5 CH 681305A5 CH 1901/92 A CH1901/92 A CH 1901/92A CH 190192 A CH190192 A CH 190192A CH 681305 A5 CH681305 A5 CH 681305A5
Authority
CH
Switzerland
Prior art keywords
antibody
column
purified preparation
cdw52
protein
Prior art date
Application number
CH1901/92A
Other languages
English (en)
French (fr)
Inventor
Paul Ian Nicholas Ramage
Geoffrey Allen
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CH681305(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of CH681305A5 publication Critical patent/CH681305A5/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CH1901/92A 1990-10-17 1991-10-17 CH681305A5 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909022547A GB9022547D0 (en) 1990-10-17 1990-10-17 Purified immunoglobulin

Publications (1)

Publication Number Publication Date
CH681305A5 true CH681305A5 (enExample) 1993-02-26

Family

ID=10683866

Family Applications (2)

Application Number Title Priority Date Filing Date
CH2655/92A CH681455A5 (enExample) 1990-10-17 1991-10-17
CH1901/92A CH681305A5 (enExample) 1990-10-17 1991-10-17

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CH2655/92A CH681455A5 (enExample) 1990-10-17 1991-10-17

Country Status (29)

Country Link
US (1) US5644036A (enExample)
EP (1) EP0504363B2 (enExample)
JP (1) JP2638680B2 (enExample)
KR (2) KR960015399B1 (enExample)
AT (2) ATE162552T1 (enExample)
AU (3) AU658926B2 (enExample)
BE (1) BE1004226A5 (enExample)
BR (1) BR1100358A (enExample)
CA (1) CA2069481C (enExample)
CH (2) CH681455A5 (enExample)
DE (1) DE69128774T3 (enExample)
DK (1) DK0504363T4 (enExample)
ES (2) ES2112865T5 (enExample)
FI (2) FI110003B (enExample)
FR (2) FR2668164A1 (enExample)
GB (2) GB9022547D0 (enExample)
GR (3) GR910100425A (enExample)
HU (1) HUT64601A (enExample)
IE (1) IE913560A1 (enExample)
IL (3) IL102726A (enExample)
IT (1) IT1250064B (enExample)
LU (1) LU88122A1 (enExample)
MX (1) MX9203794A (enExample)
MY (2) MY119030A (enExample)
NZ (2) NZ244114A (enExample)
PT (2) PT99248B (enExample)
TW (1) TW283710B (enExample)
WO (1) WO1992007084A1 (enExample)
ZA (2) ZA918259B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
ES2125977T3 (es) * 1991-10-15 1999-03-16 Btg Int Ltd Cdw52-anticuerpo especifico para el tratamiento de la inflamacion de las articulaciones mediada por celulas t.
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB9300501D0 (en) * 1993-01-09 1993-03-03 Wellcome Found Purification of immunoglobulin
CN1122531C (zh) † 1995-08-01 2003-10-01 巴斯德梅诺血清和疫苗公司 抗日本脑炎疫苗的工业生产方法和所获得的疫苗
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE122004000004I1 (de) * 1996-02-09 2004-08-12 Abott Biotechnology Ltd Humane Antikörper welche an Humanen TNFalpha binden.
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
EP3088412B1 (en) 2001-03-09 2021-05-05 Chugai Seiyaku Kabushiki Kaisha Protein purification method
WO2002098531A1 (en) * 2001-06-05 2002-12-12 Genetics Institute, Llc Methods for purifying highly anionic proteins
GB0220894D0 (en) * 2002-09-09 2002-10-16 Millipore Uk Ltd Method of separation
EP2261230B1 (en) 2002-09-11 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Protein purification method
EP2314604A3 (en) 2002-10-15 2011-05-25 Intercell AG Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
EP1696956A4 (en) * 2003-12-22 2007-08-01 Genzyme Corp ANTI-CD52 ANTIBODIES AND TREATMENT OF DIABETES
WO2006099308A2 (en) * 2005-03-11 2006-09-21 Wyeth A method of weak partitioning chromatography
IN2014DN10515A (enExample) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
MX336725B (es) 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
TWI700293B (zh) 2008-04-11 2020-08-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗體
MY160126A (en) 2009-05-13 2017-02-28 Genzyme Corp Anti-human cd52 immunoglobulins
MX342907B (es) 2009-05-13 2016-10-17 Genzyme Corp * El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus.
WO2011090719A2 (en) * 2009-12-29 2011-07-28 Dr. Reddy's Laboratories Ltd. Protein purification by ion exchange
EP3266793A1 (en) 2010-06-21 2018-01-10 Kyowa Hakko Kirin Co., Ltd. Method for purifying protein using amino acid
RU2467783C2 (ru) * 2010-07-30 2012-11-27 Закрытое акционерное общество "БиоХимМак СТ" Способ хроматографического выделения иммуноглобулина
KR102568454B1 (ko) 2010-11-30 2023-08-18 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP4671270A3 (en) 2013-12-27 2026-03-18 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
TWI656133B (zh) 2014-12-19 2019-04-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
EP3330279B1 (en) 2015-07-31 2022-04-06 Chugai Seiyaku Kabushiki Kaisha Method for purifying composition comprising antibodies with anionic polymer
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
MX392628B (es) 2016-07-25 2025-03-24 Cephalon Inc Amortiguador de lavado de cromatografia de afinidad.
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
CN113646066B (zh) 2019-03-29 2024-05-31 旭化成医疗株式会社 蛋白质的纯化方法
WO2020209267A1 (ja) 2019-04-08 2020-10-15 旭化成メディカル株式会社 タンパク質含有溶液精製用ポリアミド媒体及びその製造方法
JP7583411B2 (ja) 2019-04-10 2024-11-14 中外製薬株式会社 Ｆｃ領域改変抗体の精製方法
KR20240021151A (ko) 2021-06-10 2024-02-16 미쯔비시 케미컬 주식회사 합성 흡착제, 항체의 정제 방법 및 항체의 제조 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) * 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
EP0328404B1 (en) * 1988-02-12 1993-09-29 Btg International Limited Modified antibodies

Also Published As

Publication number Publication date
WO1992007084A1 (en) 1992-04-30
AU658926B2 (en) 1995-05-04
GB9022547D0 (en) 1990-11-28
FI110003B (fi) 2002-11-15
FI922380L (fi) 1992-05-25
GB2253397A (en) 1992-09-09
KR100193314B1 (ko) 1999-06-15
BR1100358A (pt) 2000-03-28
FI110002B (fi) 2002-11-15
MX9203794A (es) 1992-07-01
ES2112865T5 (es) 2007-09-16
HUT64601A (en) 1994-01-28
EP0504363A1 (en) 1992-09-23
ATA900791A (de) 1996-06-15
AU2532192A (en) 1993-02-11
CA2069481C (en) 2003-07-29
PT99248A (pt) 1993-06-30
ES2112865T3 (es) 1998-04-16
PT100988B (pt) 1999-08-31
GB9209529D0 (en) 1992-07-01
CH681455A5 (enExample) 1993-03-31
ES2081742B1 (es) 1996-10-01
GR910100425A (el) 1992-09-25
FR2668164A1 (fr) 1992-04-24
FR2668164B1 (enExample) 1995-04-14
IL99761A0 (en) 1992-08-18
EP0504363B2 (en) 2007-02-07
PT99248B (pt) 1999-04-30
KR960015399B1 (ko) 1996-11-13
BE1004226A5 (fr) 1992-10-13
AU7024294A (en) 1995-01-05
IE913560A1 (en) 1992-04-22
FI922380A0 (fi) 1992-05-25
PT100988A (pt) 1994-02-28
CA2069481A1 (en) 1992-04-18
TW283710B (enExample) 1996-08-21
IL102726A0 (en) 1993-01-31
MY119030A (en) 2005-03-31
ATE162552T1 (de) 1998-02-15
ITRM910788A1 (it) 1993-04-16
AU4521897A (en) 1998-02-12
NZ244114A (en) 1995-06-27
FI922824L (fi) 1992-06-17
MY136210A (en) 2008-08-29
FI922824A0 (fi) 1992-06-17
EP0504363B1 (en) 1998-01-21
JP2638680B2 (ja) 1997-08-06
IL102726A (en) 2002-08-14
US5644036A (en) 1997-07-01
LU88122A1 (fr) 1993-03-15
ES2081742A1 (es) 1996-03-01
IT1250064B (it) 1995-03-30
ZA926191B (en) 1993-04-16
GR3026588T3 (en) 1998-07-31
DE69128774T3 (de) 2007-08-16
JPH05504579A (ja) 1993-07-15
DE69128774D1 (de) 1998-02-26
ITRM910788A0 (it) 1991-10-16
DK0504363T3 (da) 1998-09-21
DK0504363T4 (da) 2007-05-29
HU9202000D0 (en) 1992-10-28
FR2677997A1 (fr) 1992-12-24
AU8729491A (en) 1992-05-20
AU649078B2 (en) 1994-05-12
ZA918259B (en) 1993-04-16
GR920100471A (el) 1994-06-30
AU716402B2 (en) 2000-02-24
DE69128774T2 (de) 1998-06-04
NZ240247A (en) 1994-03-25
KR920703108A (ko) 1992-12-17

Similar Documents

Publication Publication Date Title
BE1004226A5 (fr) Immunoglobuline purifiee.
EP1299421B1 (en) Antibodies to human mcp-1
IE84931B1 (en) Purified IgG Antibodies
EP1078005A1 (en) Methods for amyloid removal using anti-amyloid antibodies
US8197811B2 (en) Methods of use of sialoadhesin factor-2 antibodies
CN116547298A (zh) 猫抗体恒定区中的突变
US20130122022A1 (en) Sequence of stro-1 antibody variable region
CN119735674B (zh) 抗vmat2的抗体或其抗原结合片段及其组合物和应用
WO2001066126A1 (en) Sialoadhesin factor-2 antibodies
AU649078C (en) Purified CDW52-specific antibodies
OA20246A (en) Monoclonal antibodies against the beta chain region of human TRBV9.
HK1240247B (en) Anti‐transthyretin antibodies
HK1240247A1 (en) Anti‐transthyretin antibodies

Legal Events

Date Code Title Description
PL Patent ceased